SOLICITATION NOTICE
B -- Metabolomic profiling
- Notice Date
- 7/26/2006
- Notice Type
- Solicitation Notice
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive Room 1B59, Bethesda, MD, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI60087
- Response Due
- 8/14/2006
- Archive Date
- 8/29/2006
- Description
- The National Institute on Drug Abuse (NIDA), Station Support/Simplified Acquisitions (SS/SA) Branch on behalf of the National Institute of Mental Health intents to negotiate and award a purchase order on a non-competitive basis with Duke University, P.O. Box 104135, Durham, NC 27708: The following service under NACIS Code 611310 and Business Size is $6.5. Duke University has been tasked to continue the process which determines the Biochemical Changes and Define Initial Metabolic Signature for Major Depressive Disorder (MDD). The hypothesis being tested is there are biochemical changes in depression that are long lasting and that can be identified in CSF samples from patients. Determine Metabolic Signatures for Glial Cells Treated with Lithium. Duke University will metabolically analyze 18 CSF samples from healthy controls and from patients with MDD. Additionally, they will analyze 12 samples from glial cells treated with lithium. Duke University?s principal investigator, Dr. Kaddurah-Daouk, a pioneer in the field of Metabolomics. The Mood Anxiety Disorders Program (MAP) is the world? largest research program focused on mood and anxiety disorders. MAP requires the metabolic profiling of CSF from depressed subjects, as well as profiling the factors involved in mediating astocyteneuronal communication and lithium signaling. The NIMH?s Dr. Kaddurah-Daouk, is also the co-founder of the Metabolomics Society and currently serves as its first biotechnology company prior to her recent return to academia. Over the past four years, Dr. Kaddurah-Daouk has assembled a network of academic support the analysis of motor- neuron diseases (MND) as a prototypic CNS disorder for the application of Metabolornics science. She and her collaborators have succeeded in mapping the first plasma biochemical - signature for MDD, as well as a signature for the motor neuron disease drug liluzole. This sole source acquisition; therefore, is justified under the authority contained in 41 U. S.C. 253 ? (1) and FAR 6.302-1 (a) (2), states that: ?When the supplies or services required by the agency are available from only one responsible source, and no other type of supplies or services will satisfy agency requirement full and competition need not be provided for.? The acquisition is being conducted under simplified acquisition procedures using FAR 13 and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing synopsis number NOI60087 may be submitted to the NIDA, Station Support/Simplified Acquisition Branch, 31 Center Drive, Room 1B59, Bethesda, MD 20892-2080, and Attention: Rosie C. Owens, Contracting Officer
- Place of Performance
- Address: 31 Center Drive,Bethesda,Maryland
- Zip Code: 20892
- Country: UNITED STATES
- Zip Code: 20892
- Record
- SN01098168-W 20060728/060726220507 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |